Suppr超能文献

相似文献

1
Polycomb repressive complex 2 in the driver's seat of childhood and young adult brain tumours.
Trends Cell Biol. 2021 Oct;31(10):814-828. doi: 10.1016/j.tcb.2021.05.006. Epub 2021 Jun 3.
2
PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism.
Nat Commun. 2019 May 13;10(1):2146. doi: 10.1038/s41467-019-09981-6.
4
MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells.
Neuro Oncol. 2013 Sep;15(9):1212-24. doi: 10.1093/neuonc/not055. Epub 2013 Jun 3.
5
Oncohistones in brain tumors: the soil and seed.
Trends Cancer. 2023 May;9(5):444-455. doi: 10.1016/j.trecan.2023.02.003. Epub 2023 Mar 16.
6
EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
Acta Neuropathol. 2022 Jan;143(1):1-13. doi: 10.1007/s00401-021-02382-4. Epub 2021 Nov 11.
7
Polycomb repressor complex: Its function in human cancer and therapeutic target strategy.
Biomed Pharmacother. 2023 Dec 31;169:115897. doi: 10.1016/j.biopha.2023.115897. Epub 2023 Nov 17.
9
Functional roles of enhancer of zeste homolog 2 in gliomas.
Gene. 2016 Jan 15;576(1 Pt 2):189-94. doi: 10.1016/j.gene.2015.09.080. Epub 2015 Oct 20.
10
H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape.
Cell Rep. 2022 May 17;39(7):110836. doi: 10.1016/j.celrep.2022.110836.

引用本文的文献

1
A specific form of cPRC1 containing CBX4 is co-opted to mediate oncogenic gene repression in diffuse midline glioma.
Mol Cell. 2025 Jun 5;85(11):2110-2127.e7. doi: 10.1016/j.molcel.2025.04.026. Epub 2025 May 21.
2
Death-ision: the link between cellular resilience and cancer resistance to treatments.
Mol Cancer. 2025 May 15;24(1):144. doi: 10.1186/s12943-025-02339-1.
4
The role of brainstem biopsy and targeted therapies in pediatric diffuse midline glioma/diffuse intrinsic pontine glioma.
Front Oncol. 2024 Dec 23;14:1504440. doi: 10.3389/fonc.2024.1504440. eCollection 2024.
5
A scoping review of diffuse hemispheric glioma, H3 G34-mutant: Epigenetic and molecular profiles, clinicopathology, and treatment avenues.
Neurooncol Adv. 2024 Dec 7;6(1):vdae208. doi: 10.1093/noajnl/vdae208. eCollection 2024 Jan-Dec.
6
Novel insights on genetics and epigenetics as clinical targets for paediatric astrocytoma.
Clin Transl Med. 2024 Feb;14(2):e1560. doi: 10.1002/ctm2.1560.
7
Polycomb Repressive Complex 2 in Oncology.
Cancer Treat Res. 2023;190:273-320. doi: 10.1007/978-3-031-45654-1_9.
9
Ribosomal S6 protein kinase 4 promotes resistance to EZH2 inhibitors in glioblastoma.
Cancer Gene Ther. 2023 Dec;30(12):1636-1648. doi: 10.1038/s41417-023-00666-3. Epub 2023 Sep 19.

本文引用的文献

1
Dissecting the impact of regional identity and the oncogenic role of human-specific NOTCH2NL in an hESC model of H3.3G34R-mutant glioma.
Cell Stem Cell. 2021 May 6;28(5):894-905.e7. doi: 10.1016/j.stem.2021.02.003. Epub 2021 Feb 24.
2
Regional identity of human neural stem cells determines oncogenic responses to histone H3.3 mutants.
Cell Stem Cell. 2021 May 6;28(5):877-893.e9. doi: 10.1016/j.stem.2021.01.016. Epub 2021 Feb 24.
3
Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas.
Nat Commun. 2021 Feb 12;12(1):971. doi: 10.1038/s41467-021-20896-z.
4
Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells.
Neuro Oncol. 2021 Apr 12;23(4):542-556. doi: 10.1093/neuonc/noaa283.
5
Effects of H3.3G34V mutation on genomic H3K36 and H3K27 methylation patterns in isogenic pediatric glioma cells.
Acta Neuropathol Commun. 2020 Dec 7;8(1):219. doi: 10.1186/s40478-020-01092-4.
6
Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer.
Nat Commun. 2020 Dec 4;11(1):6216. doi: 10.1038/s41467-020-19972-7.
10
Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG.
Cell Rep. 2020 Oct 20;33(3):108286. doi: 10.1016/j.celrep.2020.108286.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验